Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafet Basar

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Cytotherapy|December 15, 2025
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftmentPortia Smallbone, Mayela Mendt, Robert Sackstein, et al.
Cell Reports|July 16, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
The Journal of Clinical Investigation|June 1, 2023
Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune responseMihnea P Dragomir, Enrique Fuentes-Mattei, Melanie Winkle, et al.
Blood Advances|July 28, 2020
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cellsRafet Basar, May Daher, Nadima Uprety, et al.
Frontiers in Immunology|May 21, 2021
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHDMayela Mendt, May Daher, Rafet Basar, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Cytotherapy|December 15, 2025
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftmentPortia Smallbone, Mayela Mendt, Robert Sackstein, et al.
Cell Reports|July 16, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
The Journal of Clinical Investigation|June 1, 2023
Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune responseMihnea P Dragomir, Enrique Fuentes-Mattei, Melanie Winkle, et al.
Blood Advances|July 28, 2020
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cellsRafet Basar, May Daher, Nadima Uprety, et al.
Frontiers in Immunology|May 21, 2021
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHDMayela Mendt, May Daher, Rafet Basar, et al.
Pageof 6